





HIGHLY EFFICIENT & ACCURATE

Advanced fluorescence immunoassay

Multiple quality control



REAL-TIME AND RAPID TEST

One-step test

3-15 min/test

5 sec/test for multiple tests

OPERATION MODES

Inside Mode (Single sample rapid test mode)







Test Card Insert



Click "Start" Icon



Result Show and Print

Outside Mode (Mass samples rapid test mode)



Sample Transfer



Timing the Reaction Manually



Click "Start" Icon



Result Show and Print





CONVENIENT OPERATION

RFID card calibration

Keyboard and mouse connectivity through USB port

Handwriting input available

Continuous test for 3 hours with optional lithium battery



USER-FRIENDLY INTERFACE

Android system

7-inch touch screen



- 3 Test Card Slot 5 USB Slot
- SD Card Slot
- **6** Built-in Thermal Printer

- **1** 7-inch Touch Screen
- **2** SD Card Recognition Zone





PORTABLE DESIGN

Small in size: 261*241*115 mm

Light in weight: 2.0 kg



LARGE MEMORY

Up to 10,000 results storage capacity

TECHNICAL PARAMETERS

Methodology

Immunofluorescence

Result

Quantitative

Sample Type

WB, Plasma, Serum, Urine, Stool, Nasal swab, Saliva, Capillary blood

Storage Capacity

10,000 data

Language

English/Chinese/Spanish/Portuguese

Screen

7-inch touch screen

Power Supply

100-240 V ~ 50 Hz/60 Hz, 60 VA

Working Environment

Temperature: 10-35°C Relative humidity ≤ 70% Air pressure 70.0 ~ 106.0 kpa

Dimensions

261 mm*241 mm*115 mm (D*W*H)

Weight

2.0 kg

TEST ITEMS

Cat.#	TEST ITEMS	DISEASES	CUT-OFF VALUE	Sample Types	MEASURING RANGE	SAMPLE VOLUME	REACTION TIME	QUALIFI	CATIC
Cardi	ac Markers								
IF1001	cTnl	Myocardial infarction	0.10 ng/mL	S/P/WB	0.10-50.00 ng/mL	100 μL	10 min	NMPA	CE
IF1098	TnT	Myocardial infarction	14.0 pg/mL	S/P/WB	10.0-10000.0 pg/mL	100 μL	15 min	NMPA	CE
IF1089	BNP	Heart failure	100.0 pg/mL	P/WB	5.0-5000.0 pg/mL	100 μL	10 min	NMPA	CE
IF1002	NT-proBNP	Heart failure	300 pg/mL	S/P/WB	100-35000 pg/mL	100 μL	10 min	NMPA	CE
IF1004	NT-proBNP/cTnI	Heart failure/acute myocardial infarction/acute coronary syndrome	NT-proBNP: 185 pg/mL cTnl: 0.10 ng/mL	S/P/WB	100-15000 pg/mL 0.10-50.00 ng/mL	100 μL	10 min	NMPA	(E
IF1005	CK-MB/cTnI/Myo	Myocardial damage /infarction	CK-MB: 5.00 ng/mL cTnl: 0.10 ng/mL Myo: 70.0 ng/mL	S/P/WB	2.50-80.00 ng/mL 0.10-50.00 ng/mL 30.0-600.0 ng/mL	100 μL	10 min	NMPA	CE
IF1012	CK-MB/cTnI	Myocardial damage /infarction	CK-MB: 5.00 ng/mL cTnl: 0.10 ng/mL	S/P/WB	2.50-80.00 ng/mL 0.10-50.00 ng/mL	100 μL	10 min	NMPA	CE
IF1014	H-FABP	Myocardial damage	6.36 ng/mL	S/P/WB	1.00-120.00 ng/mL	100 μL	3 min	NMPA	CE
IF1016	CK-MB/cTnI/H-FABP	Myocardial damage /infarction	CK-MB: 5.00 ng/mL cTnl: 0.10 ng/mL H-FABP: 6.36 ng/mL	S/P/WB	2.50-80.00 ng/mL 0.10-50.00 ng/mL 2.00-100.00 ng/mL	100 μL	10 min	NMPA	CE
IF1018	CK-MB	Myocardial injury	5.00 ng/mL	S/P/WB	2.50-80.00 ng/mL	100 μL	10 min	NMPA	CE
IF1087	ST2	AMI and chronic heart failure	35.0 ng/mL	S/P/WB	3.0-200.0 ng/mL	100 μL	15 min		CE
Coagu	ulation Marker								
IF1006	D-Dimer	Venous thromboembolism	0.50 mg/L	P/WB	0.10-10.00 mg/L	100 μL	10 min	NMPA	C
Inflan	nmation		<i>S</i> ,	. <u>F</u>	o,				
IF1003	hs-CRP+CRP	Cardiovascular inflammation /normal inflammation	3.0 mg/L 10.0 mg/L	S/P/WB/ Fingertip blood	0.5-200.0 mg/L	10 μL	3 min	NMPA	C
IF1007	PCT	Sepsis, bacterial infection	0.10 ng/mL	S/P/WB	0.05-50.00 ng/mL	100 μL	15 min	NMPA	C
IF1015	PCT/CRP	Sepsis, bacterial infection	PCT: 0.10 ng/mL CRP: 3.0 mg/L	S/P/WB	0.10-50.00 ng/mL 0.5-200.0 mg/L	20 μL	15 min	NMPA	(
IF1044	SAA	Bacterial/Virus infection	10.0 mg/L	S/P/WB/ Fingertip blood	5.0-200.0 mg/L	10 μL	5 min	NMPA	C
IF1090	SAA/CRP	Neonatal sepsis, Bacterial/virus infection	SAA: 10.0 mg/L CRP: 10.0 mg/L	S/P/WB/ Peripheral blood	5.0-200.0 mg/L 0.5-200.0 mg/L	10 μL	5 min	NMPA	C
IF1088	IL-6	Acute inflammation	7.0 pg/mL	S/P/WB/ Peripheral blood	1.5-4000.0 pg/mL	40 μL	15 min	NMPA	(
IF1096	hs-CRP	Cardiovascular disease, routine inflammation	Refer to user manual	S/P	0.5-200.0 mg/L	100 μL	3 min	NMPA	C
IF1139	Calprotectin	Inflammatory bowel disease	<50.0 μg/g	Fecal specimen	10.0-600.0 μg/g	100 μL	15 min		C
Renal	Function								
IF1008	CysC	Acute and chronic renal diseases	0.51-1.09 mg/L	S/P/WB	0.50-10.00 mg/L	10 μL	3 min	NMPA	C
IF1009	mAlb	Diabetic nephropathy, hypertensive nephropathy	20.0 mg/L	Urine	10.0-200.0 mg/L	100 μL	3 min	NMPA	C
IF1010	NGAL	Acute kidney injury	Serum: 200.0 ng/mL Urine: 100.0 ng/mL	S/Urine	50.0-5000.0 ng/mL	10 μL	10 min	NMPA	C
IF1011	β_2 -MG	Acute and chronic kidney diseases/tumours	0.80-3.00 mg/L	S/P/WB	0.50-20.00 mg/L	10 μL	3 min	NMPA	C
Diabe	etes Mellitus								
IF1017	HbA1c	Diabetes mellitus	3.80%-5.80%	WB	2.00%-14.00%	10 μL	5 min	NGSP IFCC	NMI
Metab	oolic Marker								
IF1031	25-OH-VD	Osteomalacia, osteoporosis	30.00-50.00 ng/mL	S/P/WB/ Capillary blood	8.00-70.00 ng/mL	20 μL	20 min	NMPA	C
IF1112	Osteocalcin	Osteoporosis	Male: 14-70 ng/mL Female:11-48 ng/mL	S/P/WB	1.5-300.0 ng/mL	100 μL	15 min		C
Thyro	id Function								
IF1024	TSH	Thyroid malfunction	0.27-4.20 μlU/mL	S/P	0.10-50.00 μIU/mL	100 μL	15 min	NMPA	C
IF1022	Т3	Hyperthyroidism, hypothyroidism	1.30-3.10 nmol/L	S/P	0.30-10.00 nmol/L	100 μL	15 min	NMPA	C
IF1023	T4	Hyperthyroidism, hypothyroidism	59.00-154.00 nmol/L	S/P	5.40-320.00 nmol/L	100 μL	15 min	NMPA	C
111023									
IF1023	fT3	Hyperthyroidism, hypothyroidism	3.10-6.80 pmol/L	S/P/WB	0.60-50.00 pmol/L	100 μL	15 min	NMPA	(

IF1055	CG+B LH FSH AMH PRL Prog esterone eradiol ers PSA PSA PSA AAFP CEA A125	Fertility PCOS, infertility evaluation PCOS, infertility evaluation and pituitary disorders Fertility, PCOS, gonadal function, precocious/late puberty Infertility, gonadal disorders Infertility, evaluation of ovulation Female polycystic ovary syndrome, male testosterone insufficiency Ovarian function Prostate cancer Prostate cancer Liver cancer, cancer of ovaries or testicles, etc. Cancer marker: colon cancer etc. Ovarian cancer Pancreatic cancer	5.1 mIU/mL Refer to User Manual Male: 1.75-7.81 ng/mL Female: 0.10-0.75 ng/mL Refer to User Manual 4.00 ng/mL 1.00 ng/mL 7.0 ng/mL 4.7 ng/mL 35.0 U/mL	S/P	5.0-100000.0 mIU/mL 0.20-150.00 mIU/mL 0.20-150.00 mIU/mL 0.10-20.00 ng/mL 0.50-200.00 ng/mL 0.10-40.00 ng/mL 0.10-16.00 ng/mL 40.0-4800.0 pg/mL 0.40-100.00 ng/mL 0.3-30.00 ng/mL 2.0-500.0 ng/mL	100 μL	10 min 15 min	NMPA NMPA NMPA NMPA NMPA	(€ (€ (€ (€ (€ (€
IF1013	CG+B LH FSH AMH PRL Prog esterone eradiol ers PSA PSA PSA AAFP CEA A125	PCOS, infertility evaluation PCOS, infertility evaluation and pituitary disorders Fertility, PCOS, gonadal function, precocious/late puberty Infertility, gonadal disorders Infertility, evaluation of ovulation Female polycystic ovary syndrome, male testosterone insufficiency Ovarian function Prostate cancer Prostate cancer Liver cancer, cancer of ovaries or testicles, etc. Cancer marker: colon cancer etc. Ovarian cancer	Refer to User Manual Male: 1.75-7.81 ng/mL Female: 0.10-0.75 ng/mL Refer to User Manual 4.00 ng/mL 1.00 ng/mL 7.0 ng/mL 4.7 ng/mL	S/P	0.20-150.00 mIU/mL 0.20-150.00 mIU/mL 0.10-20.00 ng/mL 0.50-200.00 ng/mL 0.10-40.00 ng/mL 40.0-4800.0 pg/mL 0.40-100.00 ng/mL 0.03-30.00 ng/mL	100 μL 100 μL 100 μL 100 μL 100 μL 100 μL 100 μL 100 μL	15 min 10 min	NMPA NMPA NMPA NMPA	C€C€C€C€C€
IF1056	PRL Prog esterone eradiol PSA PSA PSA AFP CEA A125	PCOS, infertility evaluation and pituitary disorders Fertility, PCOS, gonadal function, precocious/late puberty Infertility, gonadal disorders Infertility, evaluation of ovulation Fernale polycystic ovary syndrome, male testosterone insufficiency Ovarian function Prostate cancer Prostate cancer Liver cancer, cancer of ovaries or testicles, etc. Cancer marker: colon cancer etc.	Refer to User Manual Refer to User Manual Refer to User Manual Refer to User Manual Male: 1.75-7.81 ng/mL Female: 0.10-0.75 ng/mL Refer to User Manual 4.00 ng/mL 1.00 ng/mL 7.0 ng/mL 4.7 ng/mL	S/P S/P S/P S/P S/P S/P S/P S/P S/P	0.20-150.00 mIU/mL 0.10-20.00 ng/mL 0.50-200.00 ng/mL 0.10-40.00 ng/mL 40.0-4800.0 pg/mL 0.40-100.00 ng/mL 0.03-30.00 ng/mL	100 µL	15 min 10 min	NMPA NMPA NMPA	C€C€C€C€
IF1066	AMH PRL Prog psterone pradiol PSA PSA PSA AFP CEA A125	and pituitary disorders Fertility, PCOS, gonadal function, precocious/late puberty Infertility, gonadal disorders Infertility, evaluation of ovulation Female polycystic ovary syndrome, male testosterone insufficiency Ovarian function Prostate cancer Prostate cancer Liver cancer, cancer of ovaries or testicles, etc. Cancer marker: colon cancer etc. Ovarian cancer	Refer to User Manual Refer to User Manual Refer to User Manual Male: 1.75-7.81 ng/mL Female: 0.10-0.75 ng/mL Refer to User Manual 4.00 ng/mL 1.00 ng/mL 7.0 ng/mL 4.7 ng/mL	S/P S/P S/P S/P S/P S/P S/P S/P	0.10-20.00 ng/mL 0.50-200.00 ng/mL 0.10-40.00 ng/mL 0.10-16.00 ng/mL 40.0-4800.0 pg/mL 0.40-100.00 ng/mL 0.03-30.00 ng/mL	100 μL 100 μL 100 μL 100 μL 100 μL 100 μL	15 min 15 min 15 min 15 min 15 min 15 min 10 min	NMPA NMPA NMPA	C€C€C€
IF1048	PRL Prog psterone pradiol prs PSA PSA PSA AFP CEA A125	precocious/late puberty Infertility, gonadal disorders Infertility, evaluation of ovulation Female polycystic ovary syndrome, male testosterone insufficiency Ovarian function Prostate cancer Prostate cancer Liver cancer, cancer of ovaries or testicles, etc. Cancer marker: colon cancer etc. Ovarian cancer	Refer to User Manual Refer to User Manual Male: 1.75-7.81 ng/mL Female: 0.10-0.75 ng/mL Refer to User Manual 4.00 ng/mL 1.00 ng/mL 7.0 ng/mL 4.7 ng/mL	S/P S/P S/P S/P S/P S/P	0.50-200.00 ng/mL 0.10-40.00 ng/mL 0.10-16.00 ng/mL 40.0-4800.0 pg/mL 0.40-100.00 ng/mL 0.03-30.00 ng/mL	100 μL 100 μL 100 μL 100 μL 100 μL	15 min 15 min 15 min 15 min 15 min 15 min	NMPA NMPA NMPA	(€ (€
IF1071	Prog Prog Prog Prog Pradiol Prs PSA PSA AFP CEA A125	Infertility, evaluation of ovulation Female polycystic ovary syndrome, male testosterone insufficiency Ovarian function Prostate cancer Prostate cancer Liver cancer, cancer of ovaries or testicles, etc. Cancer marker: colon cancer etc. Ovarian cancer	Refer to User Manual Male: 1.75-7.81 ng/mL Female: 0.10-0.75 ng/mL Refer to User Manual 4.00 ng/mL 1.00 ng/mL 7.0 ng/mL 4.7 ng/mL	S/P S/P S/P S/P S/P	0.10-40.00 ng/mL 0.10-16.00 ng/mL 40.0-4800.0 pg/mL 0.40-100.00 ng/mL 0.03-30.00 ng/mL	100 μL 100 μL 100 μL 100 μL	15 min 15 min 15 min 15 min 10 min	NMPA NMPA	C€
F1073 Teston F1138 Estr Tumor Marker F1053 tF F1072 fF F1072 F1079 CA F1080 CA F1081 CA F1081 CA F1081 CA F1057 Ant F1058 An F1059 Ant F1064 HE F1063 Ant F1064 Ant F1063 Ant F1063 Ant F1063 Ant F1063 Ant F1064 HE F1063 Ant F1064 Ant F1064 Ant F1064 Ant F1064 Ant F1065 Ant F1064 Ant F10664 Ant F10664 Ant F10664 Ant F10664 Ant F10664 F10665 Ant F1066	posterone pradiol prs	Female polycystic ovary syndrome, male testosterone insufficiency Ovarian function Prostate cancer Prostate cancer Liver cancer, cancer of ovaries or testicles, etc. Cancer marker: colon cancer etc. Ovarian cancer	Male: 1.75-7.81 ng/mL Female: 0.10-0.75 ng/mL Refer to User Manual 4.00 ng/mL 1.00 ng/mL 7.0 ng/mL	S/P S/P S/P S/P S/P	0.10-16.00 ng/mL 40.0-4800.0 pg/mL 0.40-100.00 ng/mL 0.03-30.00 ng/mL	100 μL 100 μL 100 μL 100 μL	15 min 15 min 15 min 10 min	NMPA	C€
F1138	PSA PSA AFP CEA A125	male testosterone insufficiency Ovarian function Prostate cancer Prostate cancer Liver cancer, cancer of ovaries or testicles, etc. Cancer marker: colon cancer etc. Ovarian cancer	Female: 0.10-0.75 ng/mL Refer to User Manual 4.00 ng/mL 1.00 ng/mL 7.0 ng/mL 4.7 ng/mL	S/P S/P S/P	40.0-4800.0 pg/mL 0.40-100.00 ng/mL 0.03-30.00 ng/mL	100 μL 100 μL 100 μL	15 min 15 min 10 min	NMPA	
Tumor Marker IF1053 tF IF1072 fF IF1050 A IF1051 C IF1051 C IF1079 CA IF1080 CA IF1081 CA Infectious Dis IF1057 Ant IF1058 An IF1059 Ant IF1064 HE IF1063 Ant	PSA PSA AFP CEA A125	Prostate cancer Prostate cancer Liver cancer, cancer of ovaries or testicles, etc. Cancer marker: colon cancer etc. Ovarian cancer	4.00 ng/mL 1.00 ng/mL 7.0 ng/mL 4.7 ng/mL	S/P S/P S/P	0.40-100.00 ng/mL 0.03-30.00 ng/mL	100 μL	15 min 10 min	NMPA	C€
IF1053	PSA PSA AFP CEA A125 A19-9	Prostate cancer Liver cancer, cancer of ovaries or testicles, etc. Cancer marker: colon cancer etc. Ovarian cancer	1.00 ng/mL 7.0 ng/mL 4.7 ng/mL	S/P S/P	0.03-30.00 ng/mL	100 μL	10 min	NMPA	
IF1072	PSA AFP CEA A125 A19-9	Prostate cancer Liver cancer, cancer of ovaries or testicles, etc. Cancer marker: colon cancer etc. Ovarian cancer	1.00 ng/mL 7.0 ng/mL 4.7 ng/mL	S/P S/P	0.03-30.00 ng/mL	100 μL	10 min	NMPA	
	AFP CEA A125 A19-9	Liver cancer, cancer of ovaries or testicles, etc. Cancer marker: colon cancer etc. Ovarian cancer	7.0 ng/mL 4.7 ng/mL	S/P					
IF1051 CA IF1079 CA IF1080 CA IF1081 CA Infectious Dis IF1057 Ant IF1058 An IF1059 Ant IF1064 HE IF1063 Ant	CEA A125 A19-9	ovaries or testicles, etc. Cancer marker: colon cancer etc. Ovarian cancer	4.7 ng/mL		2.0-500.0 ng/mL	100 μL	15 min	NMPA	
F1079	A125 A19-9	colon cancer etc. Ovarian cancer		C/D					CE
IF1080 CA IF1081 CA Infectious Dis IF1057 Ant IF1058 An IF1059 Ant IF1064 HE IF1063 Ant	19-9		35.0 U/mL	S/P	2.0-500.0 ng/mL	100 μL	15 min	NMPA	CE
IF1081 CA Infectious Dis IF1057 Ant IF1058 An IF1059 Ant IF1064 HE IF1063 Ant		Pancreatic cancer		S/P/WB	2-500.0 U/mL	100 μL	15 min		CE
Infectious Dis IF1057 Ant IF1058 An IF1059 Ant IF1064 HE IF1063 Ant	11.7		27.0 U/mL	S/P/WB	2-1000.0 U/mL	100 μL	15 min		C€
IF1057 Ant IF1058 An IF1059 Ant IF1064 HE IF1063 Ant	A15-3	Breast cancer	26.2 U/mL	S/P/WB	1.5-300.0 U/mL	100 μL	15 min		CE
IF1058 An IF1059 Ant IF1064 HE IF1063 Ant	sease								
IF1059 Ant IF1064 HE IF1063 Ant	ti-HCV	Hepatitis C	1.00 S/CO	S/P	1.00-20.00 S/CO	100 μL	15 min		
IF1064 HE	nti-TP	Syphilis	1.00 S/CO	S/P	1.00-50.00 S/CO	100 μL	15 min		C€
IF1063 Ant	ti-HIV	AIDS	1.00 S/CO	S/P	1.00-1000.00 S/CO	100 μL	15 min		
	BsAg	Hepatitis B	1.00 IU/mL	S/P	1.00-100.00 IU/mL	100 μL	15 min		
	ti-HBs	Hepatitis B	10.00 mIU/mL	S/P/WB	10.00-1000.00 mIU/mL	100 μL	15 min		
IF1091 SARS-Co	V-2 Antigen	COVID-19	1.00 COI	Nasal swab		100 μL	15 min		CE
IF1047 <i>H. p</i>	pylori	H. pylori infection	5.0 ng/mL	Stool	1.0-200.0 ng/mL	10-50 mg	10 min		C€
IF1086 Influe	enza A/B	Respiratory viral infection	1.00 COI	Nasal swab		100 μL	15 min		CE
IF1136 Dengu	ie NS1 Ag	Dengue virus infection	1.00 S/CO	S/P/WB	1.00-50.00 S/CO	100 μL	15 min		CE
Specific Prote	ein and Rh	eumatism							
IF1075 I	RF	Rheumatoid arthritis	15.9 IU/mL	S/P/WB	10.0-640.0 IU/mL	10 μL	10 min	NMPA	C€
IF1076 A	ASO	Rheumatic fever, acute glomerulonephritis, group A streptococcal infection	408.0 IU/mL	S/P/WB	60.0-1370.0 IU/mL	10 μL	10 min	NMPA	C€
IF1029 Ant	ti-CCP	Rheumatoid arthritis	25.0 U/mL	S/P/WB	10.0-400.0 U/mL	10 μL	15 min		CE
Others									
	rritin	Anemia/tumors	Male: 30.00-400.00 ng/mL Female: 13.00-150.00 ng/mL	S/P	0.50-1000.00 ng/mL	10 μL	15 min	NMPA	CE
IF1069 Tota	tal IgE	Allergic disorders	Refer to User Manual	S/P/WB	1.00-2000.00 IU/mL	100 μL	15 min		C€
		Atrophic gastritis, stomach cancer	PG I < 70.0 ng/mL PG I/PG II < 3.0 ng/mL	S/P	PG I: 1.0-200.0 ng/mL PG II: 1.0-100.0 ng/mL	100 11	15 min		C€
IF1110 Cor	I/PG II		Refer to User Manual	S/P	11-1655 nmol/L	100 μL	15 min		CE

Coming soon: VB12, Folate...



Add.: No.9 Bofu Road, Luhe District, Nanjing, 211505, China Tel.: +86-25-68568508/68568594

Fax: +86-25-68568500

 $\hbox{E-mail: overseas@getein.com.cn; marketing@getein.com.cn}\\$

Web.: www.getein.com

























C € IVD

mAlb **Fast Test Kit** (Immunofluorescence Assav)

IF1009 for Getein1100 IE5009 for Getein1160

User Manual

IF2009 for Getein1600 I IF3009 for Getein1180 IF4009 for Getein1200

INTENDED USE

mAlb Fast Test Kit (Immunofluorescence Assav) is intended for in vitro quantitative determination of microalbuminuria (mAlb) in human urine samples. An elevated mAlb concentration below the proteinuric level has long been recognized as a marker of kidney disease and increased cardiovascular risk in diabetic nephropathy.

SUMMARY

Albumin is one of the major plasma proteins. In normal circumstances, albumin molecules are too large to cross the glomerular basement membrane. Therefore, albumin is usually present in very low concentration in urine. Damage to the glomerular basement membrane can alter its permeability. Albumin is then able to enter the urine. Sustained elevation of urinary albumin concentration is called microalbuminuria (mAlb), mAlb arises from increased leakage of glomerular basement membrane. So, mAlb is recognized as a marker of kidney damage. The epidemiology of microalbuminuria reveals a close association between systemic endothelial dysfunction and vascular disease, also implicating glomerular endothelial dysfunction in microalbuminuria.

Recent years, determination of mAlb is linked with increased risk for cardiovascular events rather than progression to endstage kidney diseases. It is a valuable tool for the detection if cardiovascular risk in diabetic nephropathy. Early detection of microalbuminuria in diabetics is critical because immediate intervention can slow the progression of disease.

PRINCIPI F

The test is based on the competition immune-detection method and uses an anti-human mAlb monoclonal antibody conjugated with fluorescence latex and recombi-

nant mAlb antigen coated on the test line. After the sample has been applied to the test strip, mAlb in the sample will compete with recombinant mAlb antigen on nitrocellulose matrix for fluorescence latex-labelled mAlb monoclonal antibody. As a result, the concentration of mAlb antigen in specimen shows inverse proportionally with the fluorescence intensity of mAlb

Insert test card into Getein1100/Getein1160/Getein1180 Immunofluorescence Quantitative Analyzer/Automatically inserted by Getein1200/Getein1600 Immunofluorescence Quantitative Analyzer (hereafter referred to as Getein1100, Getein1160, Getein1180, Getein1200 and Getein1600), the concentration of mAlb in sample will be measured and displayed on the screen. The value will be stored in Getein1100/Getein1160/Getein1180/Getein1200/ Getein 1600 and available for downloading. The result can be easily transmitted to the laboratory or hospital information system.

CONTENTS

- 1. A kit for Getein1100/Getein1160/Getein1180 contains:
- Package specifications: 25 tests/box, 10 tests/box 1) mAlb test card in a sealed pouch with desiccant
- 2) Disposable pipet
- 3) User manual: 1 piece/box
- 4) SD card: 1 piece/box
- 2. A kit for Getein1200/Getein1600 contains:
- Package specifications: 2×24 tests/kit, 2×48 tests/kit
- 1) Sealed cartridge with 24/48 Getein mAlb test cards
- 2) User manual: 1 piece/box
- Materials required for Getein1200/Getein1600:
- Sample diluent: 1 bottle/box
- 2) Box with pipette tips: 96 tips/box
- 3) Mixing plate: 1 piece/box
- 3. Sample diluent:
- Phosphate buffered saline, proteins, detergent, preservative, stabilizer
- 4. A test card consists of:

A plastic shell and a reagent strip which is composed of a sample pad, nitrocellulose membrane (one end of the membrane is coated with a fluorescence latex-labelled anti-human mAlb monoclonal antibodies, the test line is coated with mAlb recombinant antigen, and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Note: Do not mix or interchange different batches of kits.

APPLICABLE DEVICE

Getein1100 Immunofluorescence Quantitative Analyzer Getein1160 Immunofluorescence Quantitative Analyzer Getein1180 Immunofluorescence Quantitative Analyzer Getein1600 Immunofluorescence Quantitative Analyzer Getein1200 Immunofluorescence Quantitative Analyzer

STORAGE AND STABILITY

Store the test card at 4~30°C with a valid period of 24 months

Use the test card for Getein1100/Getein1160/Getein1180 within 1 hour once the foil pouch is opened.

For test card of Getein1200/Getein1600: if the cartridge is opened, it could be stable within 24 hours once exposed to air. If the test cards can't be used up at a time, please put the cartridge back to the foil pouch and reseal along the entire edge of zip-seal. The remaining test cards should be used up within 7 days.

PRECAUTIONS

- 1. For in vitro diagnostic use only.
- 2. Do not use the kit beyond the expiration date.
- 3. Do not use the test card if the foil pouch is damaged.
- 4. Do not open pouches until ready to perform the test.
- Do not reuse the test card.
- 6 Do not reuse the pinet
- 7. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
- 8. Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

- 1. This test can be used for urine sample.
- 2. *Urine sample* can be preserved at room temperature for 4 hours, please test it as soon as possible. If testing is delayed, urine sample may be stored up to 3 days at 2~8°C before testing.
- Do not use frozen urine sample.
- 4. Samples should be brought to room temperature before testing.
- 5. Do not use heat-inactivated samples.
- 6. SAMPLE VOLUME (for Getein1100/Getein1160/Getein-1180): 100 µL

TEST PROCEDURE

1. Collect specimens according to user manual.

2. Test card, sample and reagent should be brought to room temperature before testing.

For Getein1100:

- 3 Confirm SD card lot No. in accordance with test kit lot No., Perform "SD card" calibration when necessary. 4. Remove the test card from the sealed pouch immediately
- before use. Label the test card with patient or control identification
- 5. Put the test card on a clean table, horizontally placed. 6. Using sample transfer pipette, deliver 100 µL of sample
- into the sample port on the test card. 7. Reaction time: 3 minutes. Insert the test card into
- Getein1100 and press "FNT" button or click on "Start" icon (for Android Getein 1100) after reaction time is elapsed. The result will be shown on the screen and printed automatically

For Getein1160/Getein1180:

- 8. Confirm SD card lot No. in accordance with test kit lot No. Perform "SD card" calibration when necessary
- 9. Enter testing interface of Getein 1160/Getein1180.
- 10. Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
- 11. Put the test card on a clean table horizontally placed.
- 12. Using sample transfer pipette, deliver 100 uL of sample into the sample port on the test card.
- 13. Reaction time: 3 minutes. Insert the test card into Getein1160/Getein1180 immediately after sample loading. The analyzer will count down the reaction time and automatically test the card after reaction time is elapsed. The result will be shown on the screen and printed automatically.

For Getein1200/Getein1600:

- 14. Each cartridge for Getein1200/Getein1600 contains a specific RFID card which can calibrate automatically.
- 15. Place the sample diluent at the correct position in Getein1200/Getein1600
- 16. Place samples in the designed area of the sample holder, insert the holder and select the right test item, Getein1200/Getein1600 will do the testing and print the result automatically.

Notes:

- 1. It is required to perform "SD card" calibration when using a new batch of kits for Getein1100/Getein1160/ Getein1180.
- 2. It is suggested to calibrate once for one batch of kits for Getein1100/Getein1160/Getein1180.
- 3. Make sure the test card and the sample insertion is

correct and complete.

TEST RESULTS

Getein1100/Getein1160/Getein1180/Getein1200/Getein1 600 can scan the test card automatically and display the result on the screen. Please follow the procedure in user manual of Getein1100/Getein1160/Getein1180 for result printing. For additional information, please refer to the user manual of Getein1100/Getein1160/Getein1180/Getein1200/ Getein1600

EXPECTED VALUE

The expected normal value for mAlb was determined by testing samples from 500 apparently healthy individuals. The 95th percentile of the concentration for mAlb is 20.0 mg/L. (The probability that value of a normal person below 20.0 mg/L is 95%.)

It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

Measuring Range 10.0~200.0 mg/L Lower Detection Limit ≤10.0 ma/L Within-Run Precision ≤10% Between-Run Precision ≤15%

LIMITATIONS

- 1. As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
- 2. Samples containing interferents may influence the results. The table below listed the maximum allowance of these potential interferents.

Interferent	Creatinine	Glucose	Urea
Concentration (Max)	10 g/L	10 g/L	100 g/L

REFERENCES

- 1, Cöl M, Ocaktan E, Ozdemir O, et al, Microalbuminuria: prevalence in hypertensives and diabetics. Acta Med Austriaca, 2004, 31(1):23-29.
- 2. McTaggart MP, Price CP, Pinnock RG, et al. The diagnostic accuracy of a urine albumin - creatinine ratio point-of-care test for detection of albuminuria in primary

- care. Am J Kidney Dis. 2012, 60(5):787-794.
- 3. Denis Sviridov. Glen L. Hortin. Urine albumin measurement:Effects of urine matrix constituents. Clinica Chimica Acta, 2009, 404(2):140-143.
- 4. Reboldi G. Gentile G. Angeli F. et al. Microalbuminuria and hypertension. Minerva Med. 2005, 96(4):261-75.
- 5. EN ISO 18113-1:2011 In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements
- 6. EN ISO 18113-2:2011 In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2: In vitro diagnostic reagents for professional use.

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on mAlb Fast Test Kit (Immunofluorescence Assav) are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN ISO 15223-1:2021.

	Key to s	ymbols	used
Manufacturer		\square	Use-by date
(2)	Do not re-use	3	Date of manufacture
(i	Consult instructions for use or consult electronic instructions for use	LOT	Batch code
1	Temperature limit	IVD	In vitro diagnostic medical device
\sum	Contains sufficient for <n> tests</n>	EC REP	Authorized representative in the European Community/European Unior
CE mark		®	Do not use if package is damaged and consult instructions for use
REF	Catalogue number		

Thank you for purchasing mAlb Fast Test Kit (Immunofluorescence Assay). Please read this user manual carefully before operating to ensure proper use.

Version: WIF10-S-11



Getein Biotech Inc.

Add: No.9 Bofu Road, Luhe District, Naniing,

211505. China

Tel: +86-25-68568508

Fax: +86-25-68568500

E-mail: tech@getein.com.cn overseas@getein.com.cn

Website: www.getein.com

EC REP Lotus NL B.V.

Add: Koningin Julianaplein 10, 1e Verd, 2595AA,

The Hague, Netherlands. E-mail: peter@lotusnl.com

Tel: +31644168999